Lucentis ranibizumab: Completed Phase III enrollment

Roche (SIX:ROG, Basel, Switzerland) disclosed that last quarter its Genentech unit completed enrollment of 382 patients in the double-blind, sham injection-controlled, U.S. Phase III RIDE trial evalu...